# 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

> **NCT01048086** · PHASE2 · WITHDRAWN · sponsor: **University of Iowa**

## Conditions studied

- Neuroblastoma
- Neuroendocrine Tumor

## Interventions

- **DRUG:** Retinoic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01048086
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled because the company that pledged the drug does not yet have it available.
- **Last updated:** 2016-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048086, "90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01048086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*